Table 1 Baseline characteristics
Remifentanil group (n = 111) | Midazolam / propofol group (n = 75) | p | |
|---|---|---|---|
Age, years | 59.0 (51.0–70.5) | 58.0 (42.0–71.5) | 0.158 |
Sex, male | 51 (45.9) | 29 (38.7) | 0.405 |
Body mass index, kg/m2 | 22.0 (20.0–24.0) | 22.0 (20.0–24.5) | 0.630 |
Comorbidities | |||
Hypertension | 33 (29.7) | 17 (22.7) | 0.370 |
Diabetes mellitus | 12 (10.8) | 4 (5.3) | 0.298 |
Asthma | 1 (0.9) | 2 (2.7) | 0.730 |
Chronic obstructive pulmonary disease | 2 (1.8) | 2 (2.7) | 1.000 |
Chronic heart disease | 6 (5.4) | 4 (5.3) | 1.000 |
Pulmonary function | |||
FVC, L | 2.9 (2.4–3.5) | 3.1 (2.6–3.7) | 0.129 |
FVC, % predicted | 94.0 (85.0–102.0) | 99.0 (88.5–107.5) | 0.076 |
FEV1, L | 2.3 (1.8–2.7) | 2.4 (1.9–2.8) | 0.538 |
FEV1, % predicted | 99.0 (90.0–111.0) | 102.5 (91.0–111.0) | 0.691 |
FEV1/FVC | 78.0 (73.0–82.5) | 76.0 (71.0–82.5) | 0.726 |